BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

808 related articles for article (PubMed ID: 31740422)

  • 1. Bloodstream infection caused by KPC-producing Klebsiella pneumoniae resistant to ceftazidime/avibactam: epidemiology and genomic characterization.
    Gaibani P; Re MC; Campoli C; Viale PL; Ambretti S
    Clin Microbiol Infect; 2020 Apr; 26(4):516.e1-516.e4. PubMed ID: 31740422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic characterization of a KPC-23-producing Klebsiella pneumoniae ST258 clinical isolate resistant to ceftazidime-avibactam.
    Galani I; Antoniadou A; Karaiskos I; Kontopoulou K; Giamarellou H; Souli M
    Clin Microbiol Infect; 2019 Jun; 25(6):763.e5-763.e8. PubMed ID: 30928562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo evolution of resistant subpopulations of KPC-producing Klebsiella pneumoniae during ceftazidime/avibactam treatment.
    Gaibani P; Campoli C; Lewis RE; Volpe SL; Scaltriti E; Giannella M; Pongolini S; Berlingeri A; Cristini F; Bartoletti M; Tedeschi S; Ambretti S
    J Antimicrob Chemother; 2018 Jun; 73(6):1525-1529. PubMed ID: 29566151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emergence of ceftazidime/avibactam resistance in carbapenem-resistant Klebsiella pneumoniae in China.
    Zhang P; Shi Q; Hu H; Hong B; Wu X; Du X; Akova M; Yu Y
    Clin Microbiol Infect; 2020 Jan; 26(1):124.e1-124.e4. PubMed ID: 31494252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular analysis of clinical isolates of ceftazidime-avibactam-resistant Klebsiella pneumoniae.
    Venditti C; Butera O; Meledandri M; Balice MP; Cocciolillo GC; Fontana C; D'Arezzo S; De Giuli C; Antonini M; Capone A; Messina F; Nisii C; Di Caro A
    Clin Microbiol Infect; 2021 Jul; 27(7):1040.e1-1040.e6. PubMed ID: 33775814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne
    Shields RK; Chen L; Cheng S; Chavda KD; Press EG; Snyder A; Pandey R; Doi Y; Kreiswirth BN; Nguyen MH; Clancy CJ
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28031201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of KPC Variant and Porin Genotype on the
    Wilson WR; Kline EG; Jones CE; Morder KT; Mettus RT; Doi Y; Nguyen MH; Clancy CJ; Shields RK
    Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30617090
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Shields RK; Nguyen MH; Press EG; Chen L; Kreiswirth BN; Clancy CJ
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28242667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reversal of carbapenemase-producing Klebsiella pneumoniae epidemiology from blaKPC- to blaVIM-harbouring isolates in a Greek ICU after introduction of ceftazidime/avibactam.
    Papadimitriou-Olivgeris M; Bartzavali C; Lambropoulou A; Solomou A; Tsiata E; Anastassiou ED; Fligou F; Marangos M; Spiliopoulou I; Christofidou M
    J Antimicrob Chemother; 2019 Jul; 74(7):2051-2054. PubMed ID: 31002313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ceftazidime-Avibactam Resistance Associated with Increased
    Coppi M; Di Pilato V; Monaco F; Giani T; Conaldi PG; Rossolini GM
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31964792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Ceftazidime-Avibactam-Resistant and Carbapenem-Susceptible Klebsiella pneumoniae Strain Harboring
    Niu S; Chavda KD; Wei J; Zou C; Marshall SH; Dhawan P; Wang D; Bonomo RA; Kreiswirth BN; Chen L
    mSphere; 2020 Aug; 5(4):. PubMed ID: 32848008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing
    Zhang W; Guo Y; Li J; Zhang Y; Yang Y; Dong D; Zhu D; He P; Hu F
    Antimicrob Resist Infect Control; 2018; 7():142. PubMed ID: 30479755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic effects of ceftazidime/avibactam combined with meropenem in a murine model of infection with KPC-producing Klebsiella pneumoniae.
    Zheng M; Li FH; Liu J; Li WJ; Yin RX; Cai DT; Andrey DO; Zheng SL; Gales AC; Zhang WJ; Sun J; Liao XP; Yu Y
    J Antimicrob Chemother; 2024 May; 79(5):1069-1080. PubMed ID: 38526879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potency of Vaborbactam Is Less Affected than That of Avibactam in Strains Producing KPC-2 Mutations That Confer Resistance to Ceftazidime-Avibactam.
    Tsivkovski R; Lomovskaya O
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successive Emergence of Ceftazidime-Avibactam Resistance through Distinct Genomic Adaptations in
    Giddins MJ; Macesic N; Annavajhala MK; Stump S; Khan S; McConville TH; Mehta M; Gomez-Simmonds A; Uhlemann AC
    Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dynamic evolution of imipenem/relebactam resistance in a KPC-producing Klebsiella pneumoniae from a single patient during ceftazidime/avibactam-based treatments.
    Gaibani P; Bovo F; Bussini L; Lazzarotto T; Amadesi S; Bartoletti M; Viale P; Ambretti S
    J Antimicrob Chemother; 2022 May; 77(6):1570-1577. PubMed ID: 35373297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel KPC-166 in ceftazidime/avibactam resistant ST307 Klebsiella pneumoniae causing an outbreak in intensive care COVID Unit, Italy.
    Piazza A; Mattioni Marchetti V; Bielli A; Biffignandi GB; Piscopiello F; Giudici R; Tartaglione L; Merli M; Vismara C; Migliavacca R
    J Microbiol Immunol Infect; 2024 Jun; 57(3):457-469. PubMed ID: 38584042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emergence of ceftazidime-avibactam resistance in bla
    Zhou J; Yan G; Tang C; Liu J; Fu P; Ding L; Yang W; Guo Y; Wang C; Lu G; Hu F
    Int J Antimicrob Agents; 2024 Jun; 63(6):107163. PubMed ID: 38570018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changing Characteristics and
    Mavroidi A; Katsiari M; Likousi S; Palla E; Roussou Z; Nikolaou C; Mathas C; Merkouri E; Platsouka ED
    Microb Drug Resist; 2020 Jan; 26(1):28-37. PubMed ID: 31386596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of Klebsiella pneumoniae carbapenemase subtypes, extended-spectrum β-lactamases, and porin mutations on the in vitro activity of ceftazidime-avibactam against carbapenem-resistant K. pneumoniae.
    Shields RK; Clancy CJ; Hao B; Chen L; Press EG; Iovine NM; Kreiswirth BN; Nguyen MH
    Antimicrob Agents Chemother; 2015 Sep; 59(9):5793-7. PubMed ID: 26169413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.